We focus much of our global efforts on physician education and partnerships with leaders in the aesthetic industry, AMWC demonstrates this commitment.
Seoul, Korea (PRWEB) March 29, 2016
Lutronic, a leading innovator of aesthetic laser and energy-based technology, announced today the release of two new devices, a multitude of podium presentations, and a symposium panel featuring world-renowned physicians at the upcoming Aesthetic & Anti-aging Medicine World Congress (AMWC) annual event in Monaco. “We are looking forward to the clinical presentations as well as our symposium,” said Dr. Glen Calderhead, Vice-president, Medicoscientific Affairs at Lutronic, “We focus much of our global efforts on physician education and partnerships with leaders in the aesthetic industry, AMWC demonstrates this commitment.” Register for the symposium at http://www.lutronic.com/amwc
Podium presentations include presentations on trending topics, such as Cosmetic Gynecology, LED Adjunctive Therapies, and Skin Tightening by Dr. Florian Heydecker and Dr. Glen Calderhead. While the Lutronic sponsored symposium will focus on a 2-year study follow up in Cosmetic Gynecology, Laser Delivered Cosmeceutical Skin Rejuvenation, the Latest in Anti-aging Fractional Technology and an Introduction to new products, such as the picosecond laser, Pico+4.
At the AMWC Exhibition, C5 Hall Diaghilev, Lutronic will be showcasing the launch of two new products to compliment their growing line of devices. Lutronic is the global leader Nd:YAG laser technology, and has now applied their expertise to the next generation of Nd:YAG devices; Pico+4 the premium picosecond laser.
Picosecond devices have only recently come onto the aesthetic marketplace and have not delivered results as expected, until now; the Pico+4 is breaking the barriers to improve outcomes of cases recalcitrant to treatment by other Q-switched lasers! “In developing this picosecond device, we wanted to ensure it would deliver improved fluence ranges, along with traditional gentle fluences, for expanded treatment options,” stated Haelyung Hwang, CEO of Lutronic. “Our focus was to deliver the performance needed while maintaining the safety and efficacy physicians have grown to expect from Lutronic devices.”
Picosecond pulse is one of many factors important when it comes to treating challenging or recalcitrant pigment cases; others include fluence, beam profile and wavelength. “The right combination of these is critical when developing a premium system with the multitude of options available to address each individually challenging case.” Stated Dr. BL Goo, Naeum Dermatology and Aesthetic Clinic, Seoul, Korea, “The Pico+4 has optimized the system for best performance; it has dual technology with 2 pulse options, 4 wavelengths, and the widest range of precise settings that I can choose, which enable me to more successfully treat difficult cases.”
Pico+4 is truly a premium device that not only offers best in class features but provides performance enhancements that optimize outcomes. Lutronic worked closely with leading physicians to develop the best variety of parameters, which provide ideal treatment fluences for improved outcomes, even on recalcitrant cases where other systems had no longer achieved results.
Lutronic will also be announcing the release of enCurve, an apoptosis-inducing radiofrequency system that targets adipocytes. This non-invasive device utilizes the ideal frequency, 27.12 MHz, to selectively heat adipocytes to the optimal temperature to cause denaturation of cells, leading to adipocyte apoptosis.
EnCurve offers best in class features for safety, comfort and convenience. “The enCurve applicator can be positioned over both the abdomen and flanks at the same time, providing a hands-free procedure. Because the EnCurve is never in direct contact with the skin, no heat is transferred directly to the epidermis, and a gentle breeze from the Air Mode keeps the skin over the target area perspiration free for additional safety.” stated Dr. NARK-KYUNG RHO, Leaders Aesthetic Laser & Cosmetic Surgery Center, Korea “EnCurve is a new generation of intelligent adipocyte-targeting systems to ensure great curves with maximum comfort for the patient, and minimum stress for the operator.”
The release of these two devices, podium speakers and sponsored symposium shows Lutronic’s continued commitment to deliver quality devices for use in Europe and around the globe.
The Pico+4 platform offers both pico- and nanosecond modes with the performance of four wavelengths (1064, 532, 595 and 660 nm) to provide you with more options than ever before to address everything from standard treatments, to those hard to treat cases resistant to other Nd:YAG approaches. You can count on having the right power, pulse-width, wavelength and fluence you need for the outstanding outcomes your patients want, all from one premium platform.
Pico+4 is pending CE mark and it is not yet for sale in the US.
EnCurve utilizes a specialized frequency (27.12 MHz) to selectively target and heat adipocytes in order to cause denaturation of cells, leading to the programmed death of the targeted adipocytes. Employing smart features such as, Personalized Impedance Synchronization Application (PISA) and Air Mode, enCurve is the easy and comfortable way to reduce adipocytes through apoptosis-inducing radiofrequency.
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 15 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, rejuvenation, body/face contouring, chronic pain, healing and more.
With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 200 current and pending patents worldwide. With more than 270 employees worldwide, Lutronic has offices in the US, Korea, China, and Japan, a world-wide network of distributors, focused R&D centers in Korea, and is ever expanding.